A practical reference on mass spectrometry: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Each fission of uranium-235 releases an average of 2.43 neutrons, most commonly two or three. If at least one neutron from uranium-235 fission strikes another nucleus and causes it to fission, then the chain reaction will continue. If the reaction continues to sustain itself, it is said to be critical, and the mass of 235U required to produce the critical condition is said to be a critical mass. A critical chain reaction can be achieved at low concentrations of 235U if the neutrons from fission are moderated to lower their speed, since the probability for fission with slow neutrons is greater. A fission chain reaction produces intermediate mass fragments which are highly radioactive and produce further energy by their radioactive decay. Some of them produce neutrons, called delayed neutrons, which contribute to the fission chain reaction. The power output of nuclear reactors is adjusted by the location of control rods containing elements that strongly absorb neutrons, e.g., boron, cadmium, or hafnium, in the reactor core. In nuclear bombs, the reaction is uncontrolled and the large amount of energy released creates a nuclear explosion.
; whereas the second assumption doesn't necessary imply that ρ is constant. This second assumption only strictly requires that the time rate of change of the density is compensated by the gradient of the density, as in:
== Top scorers == Following the conclusion of the competition, Wrexham player Paul Mullin was awarded the FA Cup Golden Ball Award, commemorating him as the top scorer of the season from the extra preliminary round through to the final with eight goals.
== Safe intake levels == The Panel on Dietetic Products for the European Food Safety Authority reported safe daily limits of 2.82 mg/kg of body weight for infants, 3.39 mg/kg for small children, and 1.31 mg/kg for adults, including pregnant and breastfeeding women.
Sources: en.wikipedia.org
==== Religion ==== Talarico has been described as a progressive Christian, but has objected to the term, saying he believes not in "a progressive or conservative Christianity" but in a "Biblical Christianity." Talarico has cited his faith and the teachings of Jesus as the reason for launching his political career. He said he was following the commandments to love God and one's neighbor. He said politics is "another word for how we treat our neighbors". Talarico is a critic of Christian nationalism and has called it "a cancer on our religion". He said, "there's nothing Christian about Christian nationalism". In a 2023 guest sermon, Talarico called Christian nationalism "the worship of power—social power, economic power, political power, in the name of Christ". He has said Christian nationalists have turned Jesus "into a gun-toting, gay-bashing, science-denying, money-loving, fear-mongering fascist" and that it is "incumbent on all Christians to confront it and denounce it".
This is a big step up from previous methods which could only predict based on a single domain pair. The limitation of this method is that it relies on the training dataset to produce results. Thus, usage of different training datasets could influence the results. A caveat of most methods is the lacks negative data, e.g non-interactions for proteins which can be overcome using topology-driven negative sampling.
== Trademark dispute and grocery brand == In 2002, Boston Pizza commenced a lawsuit against Boston Market in the Federal Court of Canada over the trademark use of the word "Boston" in Canada. In its defense, Boston Market alleged that Boston Pizza's trademarks were invalid because it described a style of pizza from a specific area. The dispute continued after Boston Market ceased operations in Canada in 2004. The parties settled the dispute in 2008 under an agreement that Boston Market would not use the words "Boston" or "Boston Market" in Canada for five years for restaurants or any food or drink products (other than pre-packaged food products, but not including pizza and lasagna). Boston Market also agreed that it would not challenge Boston Pizza's use in Canada of any trademark that uses the words "Boston" or "Boston Pizza" (with certain exceptions).
Sources: en.wikipedia.org
=== Archives === Lt. John T. Alderson collection of Japan photographs Archived September 4, 2015, at the Wayback Machine. circa 1890s. 40 photographic prints (1 box) : hand colored; sizes vary. At the University of Washington Libraries, Special Collections.
== Athletic career == Maroon has competed in 8 Ironman Triathlons (Hawaii – 1993, 2003, 2008, 2010, 2013; Canada – 1995; New Zealand – 1997; Germany – 2000) and is to this day an active triathlon athlete. Dr. Maroon was inducted into the Lou Holtz Upper Ohio Valley Hall of Fame in 1999, the Western Chapter of the Pennsylvania Sports Hall of Fame in 2009 and in 2010 also to the National Fitness Hall of Fame in Chicago. For 2016, in the global ranking of Ironman athletes, Maroon ranks in 4th place in his age group. In 2022, Maroon placed second in the National Senior Games for his age group and placed first in the Chicago Triathlon for his age group.
=== Visualization === The three most popular ways of visualizing the alpha-helical secondary structure of oligopeptide sequences are (1) a helical wheel, (2) a wenxiang diagram, and (3) a helical net. Each of these can be visualized with various software packages and web servers. To generate a small number of diagrams, Heliquest can be used for helical wheels, and NetWheels can be used for helical wheels and helical nets. To programmatically generate a large number of diagrams, helixvis can be used to draw helical wheels and wenxiang diagrams in the R and Python programming languages.
According to Cantrell, the album's cover art featuring a heart surrounded by a black background was inspired by the heartbreak of Staley's death. Staley's former bandmates also thanked him in the album's liner notes. On September 6, 2011, Hank Williams III released his Attention Deficit Domination album and dedicated it to Staley. Staley's Alice in Chains bandmates have stated that one of the saddest aspects of his legacy is to hear him remembered primarily for his drug use rather than the other aspects of his personality. Kinney and Cantrell have also expressed their frustration over the Grammys ignoring Staley during their annual tribute to the musicians who have died in the past year. In 2013, Alice in Chains' drummer, Sean Kinney, added the initials "LSMS" on his drum kit, a tribute to Staley and the band's former bassist, Mike Starr, who died in 2011. The music video for Alice in Chains' 2013 single, "Voices", features a picture of Staley next to a photo of Nirvana's frontman, Kurt Cobain, at the 2:20 mark. Since Alice in Chains reunited, Jerry Cantrell started paying tribute to Staley before performing the song "Nutshell". Since 2011, Cantrell pays tribute to both Staley and Mike Starr before performing the song at concerts. In April 2017, Nancy Wilson revealed that she started writing the song "The Dragon" for Staley in the 1990s. The song was recorded in 2016 and is part of the EP of Wilson's new band, Roadcase Royale, released in 2017.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.